Mario Romeo | Precision Medicine | Best Researcher Award

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, Università degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania “Luigi Vanvitelli” 🎓, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease 🏥, and metabolic dysfunction. A recipient of over 20 international awards 🏆, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication Profile 

Orcid

Education

Dr. Mario Romeo 🎓 began his academic journey with honors, earning his Diploma di Maturità Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode 📜. He continued his excellence at the University of Campania “Luigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo 🏅 has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 🎓 and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes 🏆 at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary “CoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research Focus 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions 🥗🧠💊. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the “Bermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

IOANNIS VAMVAKARIS | Precision Medicine | Best Researcher Award

Dr. IOANNIS VAMVAKARIS, IATROPOLIS, Greece

Dr. Ioannis Vamvakaris is a distinguished Greek pathologist specializing in thoracic pathology. 🫁 He earned his MSc in Thoracic Oncology in 2013 and PhD in 2018 from Athens School of Medicine. 🎓 Since 2019, he has led the Pathology Department at Sotiria General Hospital. 🏥 He’s authored over 200 publications 📚 and co-developed Greece’s first AI software for pathology. 🤖 A reviewer for top journals (Elsevier, MDPI), he actively collaborates on global research in cancer, organoids, proteomics, and microbiome. 🌍 Recognized with the 2024 Best Researcher Award 🏆 and Sigma Xi membership, Dr. Vamvakaris continues to shape medical science with dedication and innovation.

Publication Profile

Google Scholar

Education

Dr. Ioannis Vamvakaris is a highly accomplished pathologist who began his medical journey at Sotiria General Hospital in Athens 🏥. Since 2008, he has served as a consultant in the pathology department, demonstrating unwavering dedication to thoracic pathology 🫁. He earned his MSc in Thoracic Oncology in 2013 and completed his PhD in 2018 from the Athens School of Medicine 🎓. Dr. Vamvakaris also pursued specialized training in Patient-Crisis-Emergency Management at the Berlin School of Economics 🇩🇪. His academic growth and professional excellence highlight his strong commitment to advancing medical knowledge and enhancing patient care globally 🌍.

Awards

Dr. Ioannis Vamvakaris has earned prestigious honors in recognition of his exceptional contributions to pathology and oncology research 🔬. In 2024, he was presented with the Best Researcher Award at the International Research Awards on Oncology and Cancer Research 🧬. That same year, he was inducted as an Associate Member of Sigma Xi 🧠—a globally respected scientific research honor society that recognizes excellence through nomination only. Additionally, he received the Trusted Reviewer Certificate in 2023 📄, reflecting his outstanding commitment to scientific publishing and peer evaluation. These accolades underscore his leadership and integrity in medical science 🌟.o

Research Focus

Dr. Ioannis Vamvakaris is a leading expert in thoracic pathology, with a strong research focus on lung cancer, molecular oncology, and immunopathology 🔬. His studies span non-small cell lung cancer (NSCLC), checkpoint inhibitor-induced sarcoidosis, and PD-1/PD-L1 immune responses 🧬. His collaborative work explores liquid biopsy biomarkers, xenograft models, and AI-assisted diagnostics 🤖. Passionate about translational research, he contributes to genomics, proteomics, fibrosis, and epigenetics in thoracic malignancies. His multidisciplinary efforts bridge clinical pathology and personalized medicine, advancing early diagnosis and targeted therapies 💉. Dr. Vamvakaris’ research enriches global understanding of lung diseases and thoracic oncology 🌍.

Publication Top Notes

Sarcoidosis-like reactions induced by checkpoint inhibitors

Lung tumor MHCII immunity depends on in situ antigen presentation by fibroblasts

Epithelial–mesenchymal transition in non small-cell lung cancer

Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer

Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Concurrent granulomatous hepatitis, pneumonitis and sepsis as a complication of intravesical BCG immunotherapy

Salivary inflammatory markers in tension type headache and migraine: the SalHead cohort study

Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic …

An immunohistochemical evaluation of the proteins W nt1 and glycogen synthase kinase (GSK)‐3β in invasive breast carcinomas

Pulmonary blastoma: a comprehensive overview of a rare entity

Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early …

juan iovanna | Personalized Medicine | Best Researcher Award

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. 🏅 He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. 🎓 His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. 🎓 Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. 💊 He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. 🏆 This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. 💡 Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Hui Huang | Precision Medicine | Best Researcher Award

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. 📚 He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. 🏆 A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. 🔬 His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) 📚. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories 🏅. A recipient of China’s National Science Fund for Excellent Young Scholars 🎓, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❤️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) 🔬🇨🇳. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation 🧠🫀. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages 🌍💰. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes 🚀🩺.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. 🌡️🧠🫀 She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. 📊💻 Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Assoc Prof Dr. Muhammad Raza| Medicinal Chemistry|Best Researcher Award

Assoc Prof Dr. Muhammad Razal Kotaska| Medicinal Chemistry|Best Researcher Award

Assoc Prof Dr. Muhammad Raza at University of Gujrat,Pakistan

PROFILE  

orcid

 

 

Early Academic Pursuits 🎓

Dr. Muhammad Asam Raza embarked on his academic journey with a strong foundation in the natural sciences. After completing his F.Sc. from the Board of Intermediate and Secondary Education, Gujranwala in 1998, he pursued a B.Sc. in Zoology, Botany, and Chemistry from the University of Punjab, Lahore. His profound interest in chemistry led him to continue his academic endeavors with an M.Sc. in Chemistry from the same institution, where his research centered on “Production of xylanases and cellulases in bioreactor by using Chaetomium thermophile.”

Dr. Raza’s pursuit of higher education took him to GC University, Lahore, where he earned both his M.Phil. and Ph.D. degrees in Chemistry. His M.Phil. research focused on the “Phytochemical and antioxidant screening of Mimusops elengi,” while his Ph.D. dissertation was centered on the “Extraction, structure elucidation, and microbial transformation of protease inhibitors from medicinal plants.” These early research topics highlight his passion for bioactive compounds and natural product chemistry, setting the stage for a career rich in scientific exploration.

Professional Endeavors 👨‍🏫

Dr. Raza’s academic and research career took off when he joined the University of Gujrat in 2011 as an Assistant Professor in the Department of Chemistry. Over the years, he contributed extensively to teaching and research at the institution, shaping the academic futures of numerous students. His dedication and excellence in the field of chemistry led to his promotion to Associate Professor in December 2020.

In addition to his role as a professor, Dr. Raza has held various administrative responsibilities at the University of Gujrat, including serving as the coordinator of the Four Year Degree Program in Chemistry, time table in-charge, and head examiner for the B.Sc./B.S. Program. His involvement in organizing industrial and study tours has further enriched the academic experiences of students, giving them a practical understanding of their field of study.

Contributions and Research Focus 🔬

Dr. Raza’s research portfolio is vast, focusing primarily on bioactive compounds, their purification, synthesis, and characterization. His expertise in chromatographic techniques, such as Thin Layer Chromatography (TLC), Column Chromatography, and High-Performance Liquid Chromatography (HPLC), has led to significant breakthroughs in the purification of bioactive compounds. He is also proficient in Gas Chromatography-Mass Spectrometry (GC-MS), enabling him to identify volatile compounds and elucidate the structures of synthesized and natural products.

His research interests also encompass microbial transformation, enzyme inhibition, antioxidant studies, and kinetic studies of various reactions. He has explored both natural and synthetic compounds for their antimicrobial and enzyme inhibition properties, significantly contributing to the field of medicinal chemistry. Additionally, Dr. Raza’s work on the production and characterization of xylanases and cellulases from fungal cultures demonstrates his expertise in enzyme technology, which holds potential for industrial applications.

Docking studies, using different software, have also been a significant focus in Dr. Raza’s research. This computational approach to studying molecular interactions has opened new avenues in drug design and development, further enhancing his contributions to the chemistry of biologically active molecules.

Accolades and Recognition 🏆

Throughout his career, Dr. Muhammad Asam Raza has received numerous accolades, reflecting his excellence in both academic and research fields. He was awarded a Merit Scholarship in 1997 from the District Council of Hafizabad, which was an early indicator of his potential. Later, he received the Indigenous PhD 5000 Fellowship Program from the Higher Education Commission (HEC) of Pakistan, a prestigious scholarship that supported his doctoral studies. Dr. Raza’s contributions to research were also acknowledged by the Pakistan Council for Science and Technology (PCST) with Research Productivity Awards in 2012 and 2013.

Further recognition of his expertise came when Dr. Raza was approved as a Ph.D. supervisor by the HEC, allowing him to mentor and guide future researchers in their academic pursuits. Additionally, he secured a research project worth half a million rupees from the HEC, demonstrating his ability to attract significant funding for his research endeavors.

Impact and Influence 🌍

Dr. Raza’s impact extends beyond the classroom and laboratory. His active participation in organizing national and international workshops, seminars, and symposiums has significantly contributed to the dissemination of knowledge in the scientific community. He has been instrumental in hosting events such as the “Two Days Interdisciplinary National Workshop on Chromatography & Mass Spectrometry” and the “Two Days International Symposium on Developments in Contemporary Chemistry” at the University of Gujrat.

His administrative roles have also been influential, particularly his contributions as a member of various departmental committees, including the Departmental Doctoral/MPhil Program Committee (DDMPC) and the Purchase Committee (NRPU). Dr. Raza’s participation in such committees highlights his commitment to improving the academic and research infrastructure at the University of Gujrat.

Furthermore, Dr. Raza’s work as a reviewer for scientific journals and project evaluator for research proposals under the NRPU has contributed to maintaining the standards of scientific inquiry in Pakistan. His expertise is frequently sought in assessing research proposals and reviewing academic papers, ensuring the advancement of chemistry research in the country.

Legacy and Future Contributions 🌱

Dr. Muhammad Asam Raza’s contributions to the field of chemistry, both in terms of research and teaching, have left a lasting legacy at the University of Gujrat and beyond. His commitment to advancing knowledge in bioactive compounds, enzyme inhibition, and molecular docking studies is not only reflected in his research but also in the numerous students he has mentored over the years.

Looking forward, Dr. Raza is poised to continue making significant contributions to the field of chemistry, particularly in the areas of natural product chemistry, enzyme technology, and computational drug design. His future work will likely focus on the synthesis and characterization of biologically active compounds, with potential applications in pharmaceuticals, agriculture, and biotechnology.

Dr. Raza’s legacy will undoubtedly be defined by his passion for chemistry, his dedication to teaching, and his tireless pursuit of scientific excellence, which will continue to inspire future generations of researchers.

🎓Publication 

Acetylcholine and butyrylcholine esterase inhibitory potential of newly synthesized halogenated compounds: In vitro, in silico and MD simulation

  • Authors   : emanur Yesilbağ; Muhammad Asam Raza; Zeshan Ali Sandhu; Umme Farwa; Emine Berrin Poyraz;
  • Journal    :Molecular Structure
  • Year         :2025

Advances in the Optimization of Fe Nanoparticles: Unlocking Antifungal Properties for Biomedical Applications

  • Authors   : Sandhu, Z.A.; Raza, M.A.; Alqurashi, A.; Sajid, S.; Ashraf, S.; Imtiaz, K.; Aman, F.; Alessa, A.H.; Shamsi, M.B.; Latif, M.
  • Journal    :Pharmaceutics
  • Year         :2024

Association of APO B gene polymorphisms with the development of myocardial infarction in Pakistani population

  • Authors   : Arshad, M.; Iqbal, R.; Raza, M.; Bashir, R.; Ahmed, T.; Parveen, A.
  • Journal    :Gene
  • Year         :2024

Beyond graphene: exploring the potential of MXene anodes for enhanced lithium–sulfur battery performance

  • Authors   : Zeshan Ali Sandhu; Kainat Imtiaz; Muhammad Asam Raza; Adnan Ashraf; Areej Tubassum; Sajawal Khan; Umme Farwa; Ali Haider Bhalli; Abdullah G. Al-Sehemi
  • Journal    :RSC Advances
  • Year         :2024

Biomedical properties, characterization of seaweeds species and antimicrobial activity,Propriedades biomédicas, caracterização de espécies de algas marinhas e atividade antimicrobiana

  • Authors   : Rizwan, S.; Saleem, M.; Hassan, H.U.; Raza, M.A.; Kanwal, R.; Kabir, M.; Ghaffar, R.A.; Fadladdin, Y.A.J.; Rafiq, N.; Matin, A. et al.
  • Journal    :Brazilian Journal of Biology
  • Year         :2024

Assoc Prof Dr. Karel Kotaska| Precision Medicine |Best Researcher Award

Assoc Prof Dr. Karel Kotaska|Precision Medicine|Best Researcher Award

Assoc Prof Dr. Karel Kotaska at University Hospital Motol,Czech Republic

PROFILE  

orcid

 

🎓 Early Academic Pursuits

Kotaška’s academic journey began at the Sladkovského High School in Prague, where he completed his secondary education in 1992. Following this, he embarked on an educational path that laid the foundation for his career in biochemistry. In 1997, he graduated from the Institute of Chemical Technology in Prague, earning a Dipl. Ing. in Chemistry Engineering, specializing in Biomedical Engineering. His thirst for knowledge led him to pursue postgraduate studies at the 2nd Medical Faculty of Charles University, Prague, where he specialized in Biochemistry and Pathobiochemistry, culminating in a Ph.D. in 2003. His doctoral research and thesis defense were pivotal moments in shaping his future career as a leading figure in biochemistry.

🏢 Professional Endeavors

Kotaška’s professional career has spanned over two decades, beginning in 2002 at the Department of Medical Chemistry and Clinical Biochemistry at the University Hospital Motol, one of the largest medical facilities in the Czech Republic. As a research scientist and specialist, he quickly became an integral part of the team, contributing significantly to research projects and clinical laboratory functions. In 2015, Kotaška was appointed Associate Professor in Medical Chemistry and Clinical Biochemistry at the 2nd Medical Faculty of Charles University, further solidifying his standing as an expert in his field. His role expanded into quality management, becoming an auditor and overseeing laboratory processes to ensure adherence to ISO standards and good laboratory practices.

🔬 Contributions and Research Focus

Kotaška’s research interests are broad and impactful, covering various aspects of biochemistry and clinical diagnostics. His primary research focuses on the role of natriuretic peptides in cardiovascular diseases, a field critical for advancing the understanding and treatment of heart-related conditions. He has also made significant strides in investigating biomarkers associated with cardiovascular, neurological, inflammatory, and tumor diseases.

In addition to his contributions to molecular genetics, where he has explored genetic variants linked to diseases, Kotaška is well-versed in laboratory management and external quality control. He has been involved in the harmonization and standardization of laboratory practices, ensuring that diagnostics adhere to global standards. His work in urinalysis and infrared spectroscopy has also pushed forward diagnostic capabilities in clinical biochemistry.

🏆 Accolades and Recognition

Kotaška’s impressive career has not gone unnoticed. He has received numerous grant awards for his research, including projects funded by the Grant Agency of the Ministry of Health (MH) and Charles University. His studies have ranged from investigating biomarkers for organ failure to exploring the molecular biology of neurofibromatosis and cathepsin B activity in bladder carcinoma.

Notably, his project on the biological behavior of urological malignancies, which involved long-term monitoring of tissue, serum, and urine samples, stands out as a pioneering effort in the field of cancer research. Additionally, his ongoing work since 2021 on the effect of combined treatments in chronic heart failure in animal models has further contributed to advancing therapeutic approaches.

🌍 Impact and Influence

Beyond his laboratory work, Kotaška has made substantial contributions to academia and clinical education. Since 2008, he has been involved in teaching postgraduate students and has served as a lecturer at several institutions, including the Czech Technical University, where he taught biomedical engineering and laboratory techniques until 2023. As a member of the education team in postgraduate doctoral studies, he has mentored countless students, helping shape the next generation of biochemists and medical professionals.

Kotaška’s influence extends to his role as a reviewer for several prestigious biomedical journals, such as the Central European Journal of Biology, Open Heart Journal, and Diagnostics. His expertise in statistical methods, including regression analysis, survival analysis, and data evaluation, has positioned him as a thought leader in clinical diagnostics.

📚 Publications and Peer Review

With 66 peer-reviewed publications and 12 book chapters to his name, Kotaška’s work has been widely recognized and cited in the scientific community. His publications span critical topics in clinical biochemistry, genetic research, and molecular diagnostics. His H-index of 10 reflects the significant impact of his research, with 317 citations from scholars and professionals in related fields. His commitment to advancing clinical diagnostics and biochemistry is evident in his body of work, which continues to inform and guide research in these areas.

🏅 Legacy and Future Contributions

Kotaška’s legacy is rooted in his contributions to clinical biochemistry and medical diagnostics. His work on improving diagnostic efficiency, standardizing laboratory procedures, and exploring biomarkers in diseases has set a benchmark in the medical field. As a corresponding member of prominent international organizations, such as the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) and the International Federation of Clinical Chemistry (IFCC), his influence extends beyond the Czech Republic to the global scientific community.

Karel Kotaška’s future contributions are likely to focus on further enhancing diagnostic tools and treatment methods, particularly in the fields of cardiovascular diseases and cancer research. His ongoing work in investigating the effects of innovative therapeutic treatments for chronic heart failure demonstrates his commitment to improving patient outcomes. Additionally, his leadership in laboratory standardization efforts will continue to shape the practices of clinical laboratories worldwide, ensuring that diagnostics remain accurate, efficient, and globally harmonized.

🌟 Conclusion

Karel Kotaška’s career is a testament to his dedication to advancing medical science and education. His multifaceted contributions as a researcher, educator, and laboratory manager have left a lasting impact on the fields of biochemistry and clinical diagnostics. His work continues to influence both the scientific community and clinical practices, ensuring his legacy as a leading figure in medical chemistry and clinical biochemistry for years to come.

🎓Publication 

Polycyanoacrylate (super glue) as bladder concretion in a patient after bilateral inguinal hernioplasty

  • Authors   : Karel Kotaška; Milan Polák; Antonín Brisuda; Richard Průša
  • Journal    : Annals of Clinical Biochemistry
  • Year         :2020

 

Dr. ANTHOULA LAZARIS| Precision Medicine|Best Researcher Award

Dr. ANTHOULA LAZARIS, Precision Medicine,Best Researcher Award

Dr. ANTHOULA LAZARIS, at MCGILL UNIV. HEALTH CTR,Canada

PROFILE

scopus

📚 Early Academic Pursuits :

Anthoula Lazaris began her academic journey with a B.Sc. in Microbiology and Immunology from McGill University (1983-1986), where she developed a solid foundation in the biological sciences. She continued at McGill, earning a Ph.D. in Biochemistry from the Faculty of Medicine (1988-1992). Her postdoctoral studies took her to Leiden, The Netherlands, where she further honed her expertise in Medical Biochemistry (1992-1994). This robust educational background laid the groundwork for her illustrious career in academia and biotechnology.

🏢Professional Endeavors :

Lazaris has accumulated over 30 years of combined experience in academia and industry, holding management and senior-level positions. Currently, she is a scientist at the Research Institute of the McGill University Health Centre (RI-MUHC), focusing on metastatic and metabolic diseases with an emphasis on translational research. Her career highlights include:

  • Liver Disease Biobank: In 2011, Lazaris established a Liver Disease Biobank in collaboration with Dr. P Metrakos, collecting biospecimens from patients with liver-related diseases.
  • Quebec Extracellular Vesicle Consortium: She spearheaded this consortium with Drs. Rak and Olivier, demonstrating her leadership in collaborative research initiatives.
  • CIHR Training Grant: Lazaris co-wrote and secured a substantial CIHR training grant for the Goodman Cancer Centre, illustrating her proficiency in obtaining competitive funding.

🔬Contributions and Research Focus :

Lazaris’s research contributions span several critical areas:

  • Metastatic Disease: She focuses on colorectal cancer liver metastases (CRCLM), investigating molecular mechanisms to predict therapeutic responses and developing new biomarkers.
  • Translational Research: Her work bridges basic and clinical research, aiming to translate findings into precision therapies for cancer patients. Notably, her research on predictors of therapeutic responses to antiangiogenic agents has been groundbreaking.
  • Liver Diseases: Lazaris’s research also covers hepatocellular carcinoma, cholangiocarcinomas, and NAFLD/NASH, contributing to the broader understanding of these conditions.

🏆Accolades and Recognition :

Throughout her career, Lazaris has received numerous accolades:

  • Scientific American Award: In 2002, she was recognized in the category of Research Leader in Chemical and Materials for her work on transgenic animals producing spider silk.
  • Genome Canada White Paper: She spearheaded the writing of a white paper on “Disease Mechanisms,” which was integrated into Genome Quebec’s strategic plan.
  • Scientific Publications: Her research has been published in prestigious journals like Nature and Science, highlighting her contributions to molecular biology and oncology.

🌍Impact and Influence :

Lazaris’s work has had a profound impact on both the scientific community and public health:

  • Innovations in Biotechnology: She was part of the team that demonstrated the first expression of soluble spider silk, which can be spun into fibers with remarkable mechanical properties.
  • Transgenic Research Network: As the Executive Director of the Quebec Transgenic Research Network, Lazaris unified the capabilities of researchers across Quebec, securing significant funding and fostering collaborative research.
  • Cloned Animals: She was part of the team that generated the world’s first cloned goat and Canada’s first large transgenic animal, showcasing her pioneering contributions to genetic engineering.

🌟Legacy and Future Contributions :

Anthoula Lazaris’s legacy is marked by her pioneering research, leadership in collaborative scientific endeavors, and significant contributions to translational medicine. Her work continues to influence the fields of molecular biology, biotechnology, and cancer research. Looking forward, Lazaris is expected to further her contributions to personalized medicine, leveraging her extensive experience and innovative approach to address pressing challenges in healthcare. Her dedication to translational research and collaborative spirit ensures that her impact will be felt for years to come.

🎓Publication 

Predictive biomarker discovery in cancer using a unique AI model based on set theory

Hepatic stellate cell stearoyl co-A desaturase activates leukotriene B4 receptor 2 – β-catenin cascade to promote liver tumorigenesis

    • Authors :Sinha, S., Aizawa, S., Nakano, Y., Guccione, E., Tsukamoto, H.
    • Journal   :Nature Communications
    • Year       : 2023

Targeting Liver Metastases to Potentiate Immunotherapy in MS-Stable Colorectal Cancer—A Review of the Literature

  • Authors  :, Zlotnik, O., Krzywon, L., Bloom, J., Lazaris, A., Metrakos, P.
  • Journal    :Cancers
  • Year         :  2023

Isolation of extracellular vesicles from human plasma samples: The importance of controls

  • Authors  :Tsamchoe, M., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology Journal
  • Year        :   2023

A Retrospective Study on the Role of Metformin in Colorectal Cancer Liver Metastases

  • Authors  :Rada, M., Krzywon, L., Petrillo, S., Lazaris, A., Metrakos, P.
  • Journal   : Biotechnology 
  • Year        :  2023